CHiR Therapy for Elderly DLBCL Intolerant to Chemo

The objective of exploring the application of CHiR is to evaluate its therapeutic efficacy and safety in newly diagnosed elderly patients with diffuse large B-cell lymphoma (DLBCL) aged 70 and above, and to investigate the genetic subtypes that may benefit from CHiR. The primary endpoint is the complete remission rate (CRR) at the end of 8 cycles.

Trial Details

NCT ID
NCT06764017
Phase
PHASE2
Sponsor
First Affiliated Hospital of Ningbo University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • CHiR-DEL
Locations (sample)
  • Ningbo, Zhejiang, China|29.87819,121.54945

Key Eligibility Criteria

  • Age ≥ 70 years;
  • ECOG score of 0-3;
  • Rated as unfit or frail on the simplified geriatric assessment (sGA);
  • Histologically confirmed CD20-positive diffuse large B-cell lymphoma (diagnostic criteria according to WHO 2016), excluding transformed type 2 DLBCL;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →